Kiromic BioPharma Expands Clinical Trials with Key Partnership

Kiromic BioPharma Expands Deltacel-01 Clinical Trials

Kiromic BioPharma, Inc. (OTCQB: KRBP) is thrilled to announce the activation of the University of Arizona Cancer Center (UACC) as the fifth clinical trial site for its Deltacel-01 Phase 1 trial. This trial is dedicated to evaluating the promising Deltacel™ (KB-GDT-01), focused on patients battling stage 4 metastatic non-small cell lung cancer (NSCLC) after failing standard treatments.

Partnership with the University of Arizona Cancer Center

The UACC is esteemed as one of the 57 NCI-Designated Comprehensive Cancer Centers across the United States. Dr. Ricklie Ann Julian, an Assistant Professor of Medicine at UACC, is set to lead the team as the Principal Investigator for this site.

Optimism at Kiromic BioPharma

Pietro Bersani, CEO of Kiromic BioPharma, expressed enthusiasm about this new venture, stating, "We are delighted to partner with UACC. We believe we are well-positioned to enroll the next cohort of patients, and we are optimistic that we will continue to register encouraging results during the study's expansion phase. The UACC has built a solid reputation as a leading research institution and we are eager to collaborate with their esteemed team."

Following the initiation visit at UACC, the enrollment of patients is anticipated to commence shortly.

Understanding the Deltacel-01 Trial

The ongoing Phase 1 clinical trial, titled "Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Stage 4 Metastatic Non-Small Cell Lung Cancer", involves administering two intravenous infusions of Deltacel™ alongside four courses of targeted low-dose radiation over a span of 10 days. The trial's main aim is to evaluate safety, with secondary goals assessing response rates, progression-free survival, overall survival, and disease control rates.

Deltacel™: A Promising Treatment

Deltacel™ (KB-GDT-01) represents an innovative gamma delta T-cell therapy currently being explored in the Deltacel-01 trial for stage 4 metastatic NSCLC treatment. This allogeneic product consists of donor-derived gamma delta T cells, showcasing Kiromic’s commitment to developing a robust GDT platform. Initially targeting solid tumors, with NSCLC accounting for a significant portion of lung cancer cases, Deltacel™ has shown an encouraging safety and efficacy profile, especially when paired with low-dose radiation.

The Mission of Kiromic BioPharma

Kiromic BioPharma is recognized as a fully integrated, clinical-stage biotherapeutics company leveraging its proprietary DIAMOND® artificial intelligence (AI) engine for target discovery and cell therapy development. This multi-indication allogeneic cell therapy platform aims to exploit the inherent capabilities of Gamma Delta T-cells to combat solid tumors effectively. Located in Houston, Texas, Kiromic stands at the forefront of biotherapeutic advancements.

Conclusion

The recent collaboration with the University of Arizona Cancer Center marks a pivotal moment for Kiromic BioPharma as it strives to push the boundaries of cancer treatment. The Deltacel-01 trial holds promise not only for those suffering from NSCLC but also signifies a substantial step forward in the broader field of immuno-oncology.

Frequently Asked Questions

What is the Deltacel-01 trial?

The Deltacel-01 trial is a Phase 1 clinical study assessing the safety and tolerability of gamma delta T-cell infusions for stage 4 metastatic NSCLC patients.

Where is the Deltacel-01 trial being conducted?

The trial is being conducted at multiple sites, now including the University of Arizona Cancer Center, among others.

What is the primary goal of the Deltacel-01 trial?

The primary goal is to evaluate the safety of Deltacel™ treatment in patients with advanced lung cancer.

What is Deltacel™?

Deltacel™ (KB-GDT-01) is an investigational gamma delta T-cell therapy designed to target solid tumors like NSCLC.

Who is leading the trial at the University of Arizona Cancer Center?

Dr. Ricklie Ann Julian, Assistant Professor of Medicine, is the Principal Investigator at the UACC for the Deltacel-01 trial.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.